论文部分内容阅读
LAK 在体外有溶解自身和异体靶细胞的广谱抗肿瘤活性,但在临床应用时其活性却低于体外或动物的研究,这种杀伤活性缺乏的原因还不清楚。本文研究了卵巢上皮癌病人无细胞性腹水对LAK 激活的抑制作用,并对存在的抑制活性进行了特征分析。腹水标本从患卵巢上皮癌病人(FIGO Ⅲ期或Ⅳ期)常规诊断或治疗性穿刺术获得。将三例正常供者PBM(2×10~6/ml)在含有100u/mlrHIL-2 R-10培养基中培养四天即成LAK 细胞,应用Daudi 靶细胞,以只有rHIL-2培养基中产生的LAK 活性细胞相对照,发现9例试验病人腹水标本均抑制LAK 产生,抑制活性在腹水存在(80%
LAK has a broad-spectrum anti-tumor activity of dissolving autologous and allogeneic target cells in vitro, but its activity in clinical applications is lower than that of in vitro or animal studies. The cause of this lack of killing activity is still unclear. This study investigated the inhibitory effects of acellular ascites on LAK activation in patients with epithelial ovarian cancer, and characterized the presence of inhibitory activity. Ascites specimens were obtained from routine diagnosis or therapeutic puncture of patients with epithelial ovarian cancer (FIGO stage III or IV). Three normal donor PBM (2×10 6 /ml) cultured LAK cells in 100 μg/ml rHIL-2 R-10 medium for four days, and Daudi target cells were used to obtain only rHIL-2 medium. Compared with the LAK-producing cells, 9 cases of ascites specimens were found to inhibit LAK production and inhibitory activity was present in ascites (80%)